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ht). These patients are at risk for the 
cardiomyopathy, sometimes p sing to referral for 
cardiac transpiantatioa (4.2). clli~dren with life- 
ias respond to conventional antiar- 
but many do not and 
Long-term follow-up data on young patients receiving 
amiodarone is lacking. especially in relation to patient 
growth and development of late side effects. The long-term 
beneficial effects and toxicity of amiodarone have been well 
described in adults (9). Coumel and Fidelle (IO) reported on 
132 children with a mean follow 
first 39 patients of their series reported on after a mean 
follow-up interval of 12 months (I I). The 30 patients of 
~uc~o~~ et al. (12) were followed 
This report reviews our ~~a~-te 
toxicity of amiodarone in treating patients with resistant and 
life-threatening arrhythmias. Each patient who is still receiv- 
ing amiodarone has been followed up for >18 months. 
073%K!97/90/$3.50 
a 
amp examination, was pe 
A~i~daro~e was administered orally in a dose of 
i:lfant dosage should 
we have used a higher maintenance dose of 7.5 mglkg per 
by in infants <2 years of age (keeping the dose per square 
Each patient’s dala before tr 
I122 GUCCIONE ET AL. 
LONG-TERM AMIODARONE THERAPY 
JACC Vol. 15. No. 5 
April I :I I IH-24 
Table 3. Follow-Up Data in 95 Patients 
Outcome 
Success 
Initial success with 
elective suspension 
Initial success and 
nondrug-relakd death 
Partial Success 
Side effects leadin to 
drug diaconlinualion 
fulre 
No. of Mean Duration of 
Patients Treatmenl lyr)* 
42 (43%) 3.8 (1.5-6.5) 
8 (85%) 0.8 (0.5-3.8) 
14 (15%) 1.4 (0.2-4.3) 
4 (5% 1.3 (0,4-4.3) 
12 (13%) 1.7 (0.2-4.9) 
IS (It%) 0.3 (0, I-0.6) 
pg&w~, rhe drug ws &w’ve and the patients continued to 
recsivc amio&wone; mean durwtion of treatment in this 
up was 3.8 years 1.5 to 6.5). Scvcn of these 42 
ients ~~pe~en~~d ncc of atrial flutter after at least 
9x months of successful treatment with amiodarone (Fig. 2). 
patients, the drug was successful, but it was 
ause the patient elected to have surgical treat- 
e arrhythmia (five patients) or the arrhythmia 
stopped spontaneously (three infants). 
3) Fourteen patients with conRenitu1 hcarr disease in 
whom the drug wm efective had in-hospital nonsudden 
death due to progressive heart failure at a mean of I7 months 
after beginning treatment (five after surgical repair, four after 
ical palliation and five with pulmonary vascular obstrur- 
disease or surgically noncorrcetable anatomy) (Fig, 3). 
4) in four pnfienfs, tlte drug HW~ partially @erfive, and bt 
three of thm it r~~~~ diawtitwd. Two infants had junc- 
tional cctopic tachycardia; ths first unaerwcnt succcssfrll 
catheter ablation (II) of the Wopic focus and the other 
tknt dkd suddenly while asleep a&r 3 months of amio- 
treatment, Sudden death i mmon in infants with 
) and, therefore, the 
questionable. A 20 
t-cent of @en& taking amiQdaronc by duration of 
ttment. In each time interval. all patients not taking amiodarone 
wen: ~WRW& (for example, ineffective treatment. eleclive discon- 
tinuaGon. side effects, death). 
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Figure 3, Percent of 95 patients r~~~~~~~n~ alive by dwltion of 
trcatmcnt, The mqjority of the deaths wwc ~on~~~dd~~ (see text). 
month old patient with incessant ventricular t~~~by~ard~a 
underwent successful surgical excision of ventricular tumor 
(21) after 6 months of partially effective therapy with amio- 
darone, The fourth patient, who is still re~e~viu~ amio- 
darone, is a IO year old girl with atria! ectopic ta~hy~ard~a 
due to multiple foci (22): she underwent unsuccessful SM 
cal therapy (23) at 6 years of age. Is this patient. am~odar~ne 
is now partially effective in redu~iug the rate 
cardia. 5) The drug was discontinued for side 
patients in whom it had been effective (see the discussion of 
side effects). 
6) h 1.5 p~~t~~~~t,~, t/w drrrg f’iletl. Five had incessant 
ventricular ta~by~ard~a caused by a veutri~ular tumor: four 
of these had s~bsequeut successful surgical therapy (2 I). and 
the fifth died from heart failure 3 months after the arrhylhmia 
had been successfully treated surgically. Two patients had 
ventricular arrhytnmia nd severe congestive cardiomyopa- 
thy, and both died sudd,:nly after drug discontinuation. 
ar tachy~~dia was present in two additional pa- 
ed I1 and I7 years, both with pulmonary vascular 
disease; in both, the drug was ineffective. Two patients, aged 
6 weeks and 17 years, had supraventricular tachycardia 
caused by a Kent accessory bundle. One of these patients 
with severe Ebstein’s anomaly died during an intractable 
episode of supraventricular tachycardia fter the drug had 
been discontinued: the other underwent successful surgical 
therapy (23). The drug was ineffective in two patients, one 
with atrial repair of transposition of the great arteries and 
atrial flutter (the only nonresponder in this group); the other 
had atrial ectopic tachycardia nd underwent subsequent 
successful surgical therapy (23). 
The mean duration of treatment in the unsuccessful group 
of 1% patients was 3.1 months (range 0.1 to 7). The mean 
dosage in the nonresponder group was significantly higher 
than that in the responder group (I 1.7 + 6.9 versus 6.9 + 2.9 
m&g per day: p < 0.001). Reverse T3 measurements were 
performed in these patients, and were >50 ngldl in all. The 
last two patients included in the failure group were the 
patients who died during the loading period. YEARSOFTREATWEHT 
wit91 
is the only ~~rrbytl~uii~~ 
indication for heart tr 
groups of patients, the e 
ve~tricu9ar ta~hycard~a was high (99%). 
rience, amiodarone was extremely 
treatment of resistant atria9 flutter 
(10,92,25) show a 
tachycardia. We have no corn 
prefer surgical treatment (23) 
drome instead of long-term pharma~oio~i~ therapy. Our 
results confirm the efficacy of amiodarone in the treatment of 
junctional ectopic tachycardia. This arrhythmia is associated 
with a poor prognosis when it occurs in neonates or infants 
(19). A recent multicenter study (26) showed that amio- 
darone was the antiarrhythmic drug with the highest rate of 
success in the treatment of this arrhythmia. Tberefore, we 
recommend amiodarone treatment before catheter ablative 
procedures (18) or surgical therapy (23) for junctional ec- 
Torsades de pointes has been reported in 
uring amiodarone therapy (29) and was 
documented in one teenager in our study. The 
of our patients during the loading period may be explained 
by the severe heart disease and the terminal condition of 
these patients. However, it is possible that the drug contrib- 
uted to their death. Therefore we consider it mandatory to 
hospitalize all patients for initiation of amiodarone therapy. 
All eight patients who required pacemaker implantation 
were young adults with atrial flutter after atrial repair of 
O-92), with aa overall lower inci- 
In our study, only 4% of 
side effects, in contrast to 
ts < 90 years of age (1 
atients < 90 years of age 
of patients > 90 years 
n reported in c~ildreu (lo- 
dem~Rstrat 
ne (29-35). 
our series, the incidence of thyroid dysfunction was lower 
(9%). and no patient developed symptoms. Tbyro~~ test 
results returned to the normal range in two of six patients 
after the dosage of amiodarone had been reduced. 
ioral changes, such as aggressiveness and nightm 
been interpreted to be the precursor of hyperthyro 
but our two patients with these symptoms had normai 
thyroid tests. The incidence of dose-dependent hepatic ab- 
normalities and their reproducibility in experimental animal 
models suggest a toxic effect rather than host idiosyncrasy 
(29). In our experience, the changes were tran and did 
not progress. In two of our patients, hepatic ion test 
results oorma9~~ed when the dose was reduced. 
The di@renf incidmce of side 
md elderly putienfs (occurrence of myxe 
patients MO years of age 9291) 
pharmacokinetics and pharmaco 
different ages (36). Coumel and Fidelle (IO) suggested that 
amiodarone is more rapidly metabolized in young children. 
Because severe side effects appear to be 9ess frequent in 
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young patients, if the pharmacodynamics and pharmacoki- 
wtics of amiodarone in children were better understood, it 
might be possible to devise a method for reducing toxicity in 
adults. 
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